Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children

Similar Items

• Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience
  od: Uwe Nicolay, i dr.
  Izdano: (2019-08-01)
• Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood
  od: Nakaya, Helder I., i dr.
  Izdano: (2016)
• MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
  od: Banzhoff, Angelika, i dr.
  Izdano: (2008)
• Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial
  od: Esposito, Susanna, i dr.
  Izdano: (2020)
• Influenza vaccination in children primed with MF59(®)-adjuvanted or non-adjuvanted seasonal influenza vaccine
  od: Vesikari, Timo, i dr.
  Izdano: (2015)